Piramal Imaging recently announced that it will present nine studies on the effects of Neuraceq (florbetaben F18 injection) at the Alzheimer’s Association International Annual Conference (AAIC), July 18-23, 2015 at the Walter E. Washington Convention Center in Washington, D.C. Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.
Data from these studies add to the current evidence on the clinical utility of identifying beta-amyloid (Ab) plaques in the brain. “The AAIC annual meeting is a unique gathering of researchers, physicians, advocates, patients and caregivers, all of whom are here to share information and learn about the latest research advances in the fight to improve the diagnosis and management of Alzheimer’s disease,” said in a recent press release Andrew Stephens, M.D., Chief Medical Officer of Piramal Imaging. “Piramal researchers are proud to be among the many esteemed scientists who are striving to improve the way physicians diagnose and manage this increasingly prevalent and devastating disease.”
On Wednesday 22nd of July, two studies on amyloid imaging will be presented in oral sessions. In addition to these studies, Piramal Imaging experts will debate current research and clinical cases in a symposium entitled, “The CPR of Amyloid Imaging: Clinical Assessment, Image Processing and Reimbursement,” which will take place on Tuesday, the 21st of July between 6:30 and 9:30 p.m. at the Renaissance DC Downtown Hotel.
The studies to be presented include:
– ”Do Cerebellar Plaques Influence 18F-Florbetaben Amyloid PET Scan Quantification?” Wednesday, July 22, 2015, 4:15 p.m. to 5:45 p.m. ET.
– “ Impact of Morphologically Distinct Amyloid b Deposits on 18F-Florbetaben PET Scans, July 22, 2015, 4:15 p.m. to 5:45 p.m. ET.
– “Do Cerebellar Plaques Influence 18F-Florbetaben Amyloid PET Scan Quantification?, Saturday, July 18, 2015, 12:15 p.m. to 2:15 p.m. ET.
-“ Impact of Morphologically Distinct Amyloid b (Ab) Deposits on 18F-Florbetaben (FBB) PET Scans”, Saturday, July 18, 2015, 12:15 p.m. to 2:15 p.m. ET
– “Amyloid bRelated Functional Alteration in a Frontoparietal Control Network in Cognitively Normal Elderly”, Saturday, July 18, 2015, 12:15 p.m. to 2:15 p.m. ET.
-“ Amyloid Imaging in Therapeutic Trials: The Quest for the Optimal Reference Region”, Saturday, July 18, 2015, 12:15 p.m. to 2:15 p.m. ET.
– “Amyloid b-Related Functional Alteration in a Frontoparietal Control Network in Cognitively Normal Elderly”, Monday, July 20, 2015, 9:30 a.m. to 4:15 a.m. ET.
– “Alzheimer’s Biomarkers in Daily Practice (ABIDE): Study Design”, Tuesday, July 21, 2015, 9:30 a.m. to 4:15 p.m. ET
– “ A Study of Optimal SUVR Cutpoints and Reference Regions for Florbetaben PET”, Wednesday, July 22, 2015, 9:30 a.m. to 4:15 p.m. ET.
Neuraceq is a breakthrough scanning system with a negative result indicative of sparse to absent amyloid neuritic plaques in the brain,translating into no signs of AD at the time of the scan. A positive result suggests moderate to highly frequent amyloid neuritic plaques in the brain, indicating that the patient is at increased risk of AD or other neurological conditions with cognitive impairment symptoms.